Free Trial
Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka!

Top 10 Key Players companies in Ribociclib
by Highest Patent Value in the China in 2022

The Ribociclib top 10 is Discovery PatSnap’ annual ranking of the top 10 Highest Patent Value Ribociclib Key Players in the China. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2022, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
Ribociclib (trade name Kisqali) is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer. It is also being studied as a treatment for other drug-resistant cancers. It was developed by Novartis and Astex Pharmaceuticals.
#
Company Name
Region
Tech Topics
Total
1
Suzhou Miracpharma Technology Co., Ltd.
Avg patent value: 280,000
2
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Medicine,Cetuximab,Bevacizumab,
...[+2]
Avg patent value: 160,000
3
Shanghai Yaoda Biotechnology Co., Ltd.
Avg patent value: 110,000
4
Chunghwa Chemical Synthesis & Biotech Co., Ltd.
Pharmaceutical manufacturing,Pharmacy,Medicine,
...[+2]
Avg patent value: 71,000
5
Xinfa Pharmaceutical Co. Ltd.
Folic acid,Chemical engineering,Seasoning
Avg patent value: 23,000
6
Crystal Pharmatech Co., Ltd.
Contract research organization,Health care,Liposome,
...[+2]
Avg patent value: 3,600
7
Changzhou Pharmaceutical Factory Co., Ltd.
Rosuvastatin,Medicine,Active ingredient,
...[+1]
Avg patent value: 3,600
8
Chongqing Sansheng Industrial Co., Ltd.
Gypsum,Construction engineering,Sulfuric acid,
...[+1]
Avg patent value: 3,500
9
Formosa Laboratories, Inc.
Medicine,Oncology drugs,Active ingredient,
...[+2]
Avg patent value: 3,400
10
Guangan Kate Pharmaceutical Co., Ltd.
Avg patent value: 3,400
Page generation time: Jul 07 2025